07:00 , Oct 25, 2012 |  BC Innovations  |  Cover Story

Melanoma's hidden act

Researchers at the University of Bonn and the Johannes Gutenberg University Mainz have shown that melanoma cells can acquire resistance to adoptive T cell transfer therapies by dedifferentiating themselves to hide antigens.1 The group now...
08:00 , Feb 11, 2010 |  BC Innovations  |  Tools & Techniques

Synthetic saponins

Memorial Sloan-Kettering Cancer Center researchers have designed vaccine adjuvants that are synthetic derivatives of Antigenics Inc.'s QS-21,1 a purified fraction of a plant extract containing a mixture of two natural saponin isomers. The team thinks...
07:00 , Apr 15, 2003 |  BC Extra  |  Clinical News

CancerVax resumes Phase III enrollment

CancerVax (Carlsbad, Calif.) said the FDA released a partial clinical hold on enrollment in the company's international Phase III trials of Canvaxin for post-surgical treatment of patients with stage III or IV melanoma. In May...
08:00 , Feb 3, 2003 |  BC Week In Review  |  Clinical News

Canvaxin regulatory update

The FDA granted Fast Track designation to CancerVax's Canvaxin vaccine for the post-surgical treatment of metastatic melanoma. Canvaxin is in two Phase III trials in patients with Stage III or IV melanoma. The trials are...
08:00 , Jan 13, 2003 |  BC Week In Review  |  Clinical News

Canvaxin: Phase II data; 2 Phase III trials on hold

Researchers published in the Journal of Clinical Oncology a previously reported U.S. Phase II study of Canvaxin in 263 patients who had undergone complete resection of clinically detectable Stage IV melanoma showed the median overall...
08:00 , Dec 16, 2002 |  BC Week In Review  |  Clinical News

Canvaxin: Phase II data; 2 Phase III trials on hold

In a U.S. Phase II trial in 2,602 patients that underwent lympadenectomy to treat Stage III melanoma, a retrospective matched-pair analysis showed the median overall survival between Canvaxin-treated patients and non-treated patients was 55.3 months...
07:00 , Sep 5, 1995 |  BC Week In Review  |  Clinical News

Melanoma vaccine data

Researchers at the John Wayne Cancer Institute (Santa Monica, Calif.) reported a retrospective analysis over 22 years of 984 patients treated for melanoma metastasized to the lung or chest, of which 106 were treated...